Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23726307 | 0.90 | ERN1 (0.37) | ERN1CD274PDCD1PDCD1LG2FGFR3 | |
| SCHEMBL28903244 | 0.89 | ERN1 (0.37) | ERN1CD274PDCD1LG2FGFR3KDR | |
| SCHEMBL23725377 | 0.87 | CD274 (0.37) | ERN1FYNCD274PDCD1PDCD1LG2 | |
| SCHEMBL28903277 | 0.86 | ERN1 (0.37) | ERN1FYNCD274PDCD1PDCD1LG2 | |
| SCHEMBL23725690 | 0.85 | CD274 (0.37) | CD274PDCD1PDCD1LG2FGFR3KDR | |
| SCHEMBL23725657 | 0.85 | CD274 (0.36) | ERN1CD274PDCD1PDCD1LG2FGFR3 | |
| SCHEMBL28903341 | 0.85 | CD274 (0.36) | ERN1CD274PDCD1PDCD1LG2FGFR3 | |
| SCHEMBL23725863 | 0.85 | CD274 (0.35) | ERN1FYNCD274PDCD1PDCD1LG2 | |
| SCHEMBL23725994 | 0.83 | CD274 (0.35) | ERN1FYNCD274PDCD1PDCD1LG2 | |
| SCHEMBL27080638 | 0.81 | ERN1 (0.34) | ERN1FYNCD274PDCD1PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | ERN1 3525/4885FYN 3467/4885CD274 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.